Keywords
Neurodegenerative Diseases
Alzheimer Disease
Neurobehavioral Manifestations
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To report a case of behavioral variant Frontotemporal Dementia (FTD) which not infrequently, is misdiagnosed and treated as it if Alzheimer's disease (AD). Clinical detail: This is a 65-year-old patient, who started with dementia in 2019, manifested by amnesia, irritability and loss of functionality associated with a sudden change in lifestyle (severe alcoholism and obstinacy/love addiction). At our first evaluation in 2021(Month), she had a previous diagnosis of AD being treated with a cholinesterase inhibitor (IChE) for about 1 year. However, with little or no response. After a detailed anamnesis, with psychometric scales administrated, neuroimaging and CSF analysis, it was verified that the main diagnostic hypothesis is DFT, making it possible, then, to think about a right diagnosis, adapting the therapy. Final considerations: AD and FTD may have similar clinical signs and cause doubt and misdiagnosis. Assertive management and treatment are essential because they are different in both cases. Therefore, making the correct diagnosis and treatment allows effective control of the signs and symptoms of these conditions.
References
BERTOLUCCI PHF, et al. Desempenho da população brasileira na bateria neuropsicológica do Consortion to Establish a Registry for Alzheimer´s Disease (CERAD). Revista de Psiquiatria Clínica, 1998; 25(2): e80-83.
BRUCKI SMD, et al. Sugestões para o uso do miniexame do estado mental no Brasil. Arq. Neuropsiquiatra, 2003; 61(3B): e777-781.
CHRISTIDI F, et al. Social Cognition Dysfunctions in Neurodegenerative Diseases: Neuroanatomical Correlates and Clinical Implications. Behavioural Neurology, 2018.
CRISTINE SILVA P. Medicamentos contendo cloridrato de Donepezila para tratamento da doença de Alzheimer, Monografia (Graduação em Farmácia) - Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, 2022; 20-32p.
CRITCHLEY M. The parietal lobes. London: Arnold, 1953; 480p.
CRUTS M, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature, 2006; 442(7105): e920-924.
CRUZ DE SOUZA L, et al. Diagnóstico da demência frontotemporal: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. Dement Neuropsychol, 2022; 16(3): e40-52.
CUMMINGS JL, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology, 1994; 44(12): e2308-2314.
DEVENNEY EM, et al. Frontotemporal dementia. Handb Clin Neurol, 2019; 167: e279-299.
ERKKINEN MG, et al. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb Perspect Biol, 2018; 10(4): e033118.
FALGÀS N, et al. Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment. Neuroimage Clin, 2019; 23: e101927.
FINGER E. Frontotemporal Dementias. Continuum Journal, 2016; 22(2): e464–489.
GROSSMAN M, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol, 2005; 57(5): e721-729.
HERRERA EJR, et al. Epidemiologic survey of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord, 2002; 16(2): e103-108.
IBAÑEZ A e MANES F. Contextual social cognition and the behavioral variant of frontotemporal dementia. Neurology, 2012; 78(17): e1354–1362.
LISCIC RM, et al. Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias. Arch Neurol, 2007; 64(4): e535–540.
MAGILA C e CARAMELLI P. Funções executivas no idoso. São Paulo: Atheneu, 2001; 517-525p.
MATIOLI MNPS e CARAMELLI P. Limitations in differentiating vascular dementia from Alzheimer's disease with brief cognitive tests. São Paulo: Arquivos De Neuro-psiquiatria, 2010; 68(2): e185–188.
MEETER LH, et al. Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol, 2017; 13(7): e406-419.
MILLER BL, et al. A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations. Neurology, 1997; 48: e937-942.
MORRIS JC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): Part I. Clinical and neuropsychological assessment of Alzheirmer’s disease. Neurology, 1989; 9: e1159-1165.
OLNEY NT, et al. Frontotemporal Dementia. Neurologic Clinics, 2017; 35(2): e339–374.
ONYKE CU e DIEHL-SCHMID J. The epidemiology of frontotemporal dementia. International Review of Psychiatry, 2013; 25(2): e130–137.
PANG W e FENGHUA H. Cellular and physiological functions of C9ORF72 and implications for ALS/FTD. J Neurochem, 2021; 157(3): e334-350.
PATERSON RW, et al. O líquido cefalorraquidiano no diagnóstico diferencial da doença de Alzheimer: utilidade clínica de um extenso painel de biomarcadores em uma clínica cognitiva especializada. Alz Res Therapy, 2018;10(32).
PFEFFER RI, et al. Measurement of functional activities in older adults in the community. Journal of Gerontology, 1982; 37(3): e323-329.
RASCOVSKY K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 2011; 134(9): e2456-2477.
ROHRER JD, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology, 2009; 73(18): e1451-1456.
SWIFT IJ, et al. Fluid biomarkers in frontotemporal dementia: past, present and future. Journal of Neurology, Neurosurgery & Psychiatry, 2020; 92(2): e204-215.
WANG J, et al. The Advance on Frontotemporal Dementia (FTD)'s Neuropathology and Molecular Genetics. Mediators Inflamm, 2022; 2022: e500390.